Session 5:
Next Generation in Imaging in Localized Prostate Cancer

 

Session Moderator

  1. Hydrogel spacing is rapidly becoming standard of care for prostate cancer radiotherapy with growing adoption by the urology community.
  2. Hydrogel technology may be applied to other organs throughout the body that could benefit from marking or space creation (i.e. bladder, gynecological, and pancreatic cancers).
  3. Opportunities exist for clinical investigation of adjacent prostate indications (i.e. post prostatectomy, ablative therapies).
  4. Prostate MRI continues to serve an important role in the evaluation of primary disease. Clinical trial data such as PRECISION and PROMIS continue to emerge that will solidify and expand the use of prostate MRI. Standardization and variability of prostate MRI remains problematic and will hopefully improve with increased adoption of PI-RADS Version 2.
  5. Preliminary evidence regarding the use of PET/CT for the characterization of primary prostate cancer is promising however clinical trial data is necessary to prove the performance and clinical utility of the tool in the management of prostate cancer patients.

Phillip J. Koo, MD

Banner MD Anderson Cancer Center
Phoenix, Arizona

ABOUT THE AUTHOR

Phillip J. Koo, MD

Phillip J. Koo, MD, is the Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Phoenix, Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine in Aurora, Colorado. Dr. Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian and his radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System in Philadelphia, Pennsylvania. He completed his fellowship at the Harvard Medical School Joint Program in Nuclear Medicine in Boston, Massachusetts. Dr. Koo is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine(ABNM). His academic interests have focused on PET imaging in prostate cancer, response to novel therapies using PET, and data-driven motion correction. He has lectured nationally and internationally on topics related to imaging and radiopharmaceutical based therapies in prostate cancer. In 2022, Dr. Koo was the recipient of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Presidential Distinguished Service Award.